LIF and breast cancer: Our results further showed that blocking the AKT signaling by either treatments of MK2206 and Wortmannin or expression of AKT-DN greatly reduced glucose uptake (Fig. 7A, B) and lactate production (Fig. 7C, D), and largely abolished the increased glucose uptake (Fig. 7A, B) and lactate production (Fig. 7C, D) promoted by LIF in breast cancer cells.